/
PRESS RELEASE
Biotest opens new plasma collection centre in Kearney, Nebraska, USA
- 13 plasma collection centres in Europe
- 22 in the US to ensure long-term plasma supply
Dreieich, 1 December 2016. Biotest Pharmaceuticals Corporation, Boca Raton, USA (BPC), a 100% subsidiary of Biotest AG, Germany, a leading manufacturer of plasma proteins and biological products, is pleased to announce the addition of its newest plasma collection centre located at Kearney, Nebraska, USA. The state-of-the-art facility officially opened its doors for business on November 29, 2016 and brings the total number of BPC's plasma collection centres to 22.
Ileana Carlisle, BPC's Chief Executive Officer said "We are pleased to become a part of Kearney's growing community and look forward to being an active member here. This facility is just one more step forward in our resolve to better serve the thousands of patients worldwide who lives are enhanced through plasma-based therapies."
BPC has invested approximately EUR1.7 million in the construction of this facility. The Company expects to add over 40 jobs to the Kearney local economy and currently has employment opportunities available for medical personnel and phlebotomists.
About human blood plasma
Human blood plasma is a raw material used to produce plasma derived products, which are used to treat various illnesses of the immune system, the blood system, as well as in emergency medicine. Biotest is one of the world's six largest manufacturers of plasma protein products.
About Biotest
Biotest is a provider of plasma proteins and biological drugs. With a value added chain that extends from pre-clinical and clinical development to worldwide sales, Biotest has specialised primarily in the areas of clinical immunology, haematology and intensive medicine. Biotest develops and markets immunoglobulins, coagulation factors and albumins based on human blood plasma. These are used for diseases of the immune and haematopoietic systems. In addition Biotest develops monoclonal antibodies in the indications of cancer of plasma cells and systemic lupus erythematosus which are produced by recombinant technologies. Biotest has more than 2,500 employees worldwide. The preference shares of Biotest AG are listed in the SDAX on the Frankfurt stock exchange.
IR contact
Dr. Monika Buttkereit
phone: +49-6103-801-4406
email: investor.relations@biotest.com
PR contact
Dirk Neumüller
phone: +49-6103-801-269
email: pr@biotest.com
Biotest AG, Landsteinerstr. 5, 63303 Dreieich, Germany, www.biotest.de
Ordinary shares: securities' ID No. 522720; ISIN DE0005227201
Preference shares: securities' ID No. 522723; ISIN DE0005227235
Listing: Prime Standard
Open Market: Berlin-Bremen, Düsseldorf, Frankfurt, Hamburg, Hanover, Munich, Stuttgart
Disclaimer
This document contains forward-looking statements on overall economic development as well as on the business, earnings, financial and assets position of Biotest AG and its subsidiaries. These statements are based on current plans, estimates, forecasts and expectations of the company and are thus subject to risks and elements of uncertainty that could result in significant deviation of actual developments from expected developments. The forward-looking statements are only valid at the time of publication. Biotest does not intend to update the forward-looking statements and assumes no obligation to do so.
2016-12-01 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.
Archive at www.dgap.de
